Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of posaconazole versus voriconazole for invasive aspergillosis in adults and adolescents
MOH_2017-06-20_000536Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in invasive aspergillosis (IA) comparing MK-5592 / Noxafil arm with Voriconazole / VFEND arm (2 arms). Primary endpoints: Safety of intravenous and tablet posaconazole and Comparative treatment effect on invasive aspergillosis. Started Apr 2013; status: active, not recruiting.
02
Drugs
posaconazolevoriconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on MOH_2017-06-20_000536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-20_000536.